Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 15/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31702485 | 0.83 | OPRD1 (0.40) | SLC9A1HTR2CSLC6A3CYP2C9KCNH2 | |
| SCHEMBL1763854 | 0.82 | RBP4 (0.55) | SLC9A1HTR2CSLC6A3ADRA1DHTR2A | |
| SCHEMBL8276711 | 0.81 | HTR2C (0.47) | HTR2CSLC6A3CYP2C9KCNH2CYP2D6 | |
| SCHEMBL31701648 | 0.80 | SLC6A4 (0.47) | SLC6A3CYP2C19CYP3A4KCNH2CYP2D6 | |
| SCHEMBL31701871 | 0.78 | HTR2C (0.51) | HTR2CSLC6A3HTR2AHTR1ASLC6A2 | |
| SCHEMBL1764034 | 0.76 | SLC9A1 (0.46) | SLC9A1HTR2CSLC6A3ADRA1DHTR2A | |
| SCHEMBL1763870 | 0.75 | CHRNB2 (0.51) | SLC9A1HTR2CSLC6A3ADRA1DHTR2A | |
| SCHEMBL5541872 | 0.75 | HTR2C (0.61) | HTR2CSLC6A3HTR1ASLC6A2SLC6A4 | |
| SCHEMBL30439790 | 0.75 | SLC9A1 (0.55) | SLC9A1SLC6A3ADRA1DHTR2ASLC9A2 | |
| SCHEMBL17134229 | 0.75 | SLC9A1 (0.55) | SLC9A1SLC6A3ADRA1DHTR2ASLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | SLC9A1 2999/4885HTR2C 2791/4885SLC6A3 4188/4885 |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, STAT1, STAT5B | SLC9A1 2174/4885HTR2C 4066/4885SLC6A3 4639/4885 |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, NCOR1, NCOR2 | SLC9A1 2109/4885HTR2C 1604/4885SLC6A3 3979/4885 |
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | SLC9A1 3119/4885HTR2C 3053/4885SLC6A3 4376/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | SLC9A1 1121/4885HTR2C 650/4885SLC6A3 3679/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | SLC9A1 2999/4885HTR2C 2791/4885SLC6A3 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.